Smithkline Beecham Corporation

Altavant Sciences Gmbh

Daniel Patterson

Amarjit Sab Randhawa

David Igo

Shanie Everts

Paul R Johnson

There is a crystalline compound of (S)-ethyl 8-(2-amino-6-((R)-1-(5-chloro-[1,1'-biphenyl]-2-yl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)-2,8-diazaspiro[4.5]decane-3-carboxylate that exhibits an XRPD pattern having a characteristic peak at 19.05&#xb1;0.20 (&#xb0; 2&#x3b8;). There is also a pharmaceutical composition containing the compound. There is also a dosage form containing the crystalline compound and one or more pharmaceutically acceptable excipients. There is also a method for crystallizing/recrystallizing the compound. There is also a method for treating or preventing a disease with the compound.

Crystalline spirocyclic compound, a dosage form containing, a method for using in treatment of disease, and a method for recrystallizing

The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-&#x3b2;-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.

Growing community of inventors

Durham, NC, United States of America

Daniel Patterson